Hazards after discontinuation of sotoracib (AMG510)

Sotorasib (AMG510, Sotorasib) is a targeted therapy drug mainly used to treat patients with non-small cell lung cancer (NSCLC) carrying KRAS G12C mutations. KRAS mutation is one of the common gene mutations in various cancers, and sotoraxib prevents the proliferation and growth of cancer cells by specifically inhibiting the activity of the KRAS G12C mutant protein. Sotoraxib may begin to slow the progression of lung cancer immediately after taking it. But it can take several weeks for tumors to stop growing or shrink in size.

Sotorasiib controls cancer progression by inhibiting the activity of the KRAS G12C mutation. Once treatment is discontinued, KRAS-mutant cancer cells may become active again, leading to disease recurrence or progression. This is particularly risky for patients who rely on this drug to control their cancer. Long-term use of targeted therapy drugs may cause new mutations in cancer cells, rendering the drugs ineffective. Once the drug is discontinued, this resistance may be further exacerbated because cancer cells, without drug pressure, may quickly adapt to their new environment and become more difficult to treat.

Some patients may experience tumor shrinkage and symptom relief while receiving sotoraxib. Once the drug is stopped, the tumor may grow back, causing the patient's symptoms to worsen, including difficulty breathing, chest pain, fatigue, etc. For those patients who respond well to sotoraxib, discontinuation of the drug may result in a significant decrease in quality of life.

In some cases, cancer cells may resist the effects of sotoraxib by activating alternative signaling pathways. After discontinuation of medication, these alternative pathways may become more active, making subsequent treatment more difficult. Therefore, discontinuation of sotorasiib requires careful consideration and should be done under the guidance of a doctor.